Axxam and Fulcrum Therapeutics Initiate a Partnership for the Provision of Drug Discovery Services for Genetic Diseases
February 1st, 2017 – Axxam SpA (Milan/Italy), an innovative Partner Research Organization (iPRO) and leading provider of discovery services has entered into an agreement with Fulcrum Therapeutics Inc., a U.S.-based biotech founded in July 2016 by Third Rock Ventures. Fulcrum Therapeutics is focused on discovering and developing small molecule therapies to unlock gene control and the collaboration will utilize Axxam’s world-leading screening platform to identify novel targets for regulating gene expression. The programme will initially focus on genetic diseases where no effective treatment options currently exist.